Patient Square-backed Enavate Sciences led a $100m Series B funding round in CAMP4 Therapeutics.

Patient Square-backed Enavate Sciences, a firm committed to invest in and support the strategic growth of innovative therapeutic and enabling technology companies, led a $100m Series B funding round in CAMP4 Therapeutics, a biotechnology company, with participation from Gaingels, 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz and The Kraft Group. “We see immense opportunity and value in CAMP4’s truly unique approach of upregulating gene expression using antisense oligonucleotides, a proven modality for regulating gene expression. Groundbreaking insights into regRNAs, powered by internally-derived machine learning algorithms, and our ability to drug targets with ASOs have merged together in CAMP4’s proprietary platform to advance an entirely new class of medicines. We’re excited to lead this financing and partner with CAMP4 to help realize the full potential of RNA actuators for patients with genetic diseases," James Boylan, Enavate Sciences CEO.